I G Petrochemicals Limited Overview
I G Petrochemicals is India's largest producer of phthalic anhydride (PAN), the building block for phthalate plasticisers, alkyd and unsaturated polyester resins, and pigments. Commonly cited estimates put its share of the domestic market at about 50%. All production sits in one integrated complex at Taloja, near Mumbai's ports. The complex has five PAN plants with 2,22,110 MTPA of installed capacity, which places IGPL among the largest single-site PAN producers globally. It also has four small maleic anhydride (MAN) units that recover MAN from PAN process wash water; IGPL describes itself as India's only MAN producer. Benzoic acid and diethyl phthalate (DEP) complete the derivative range. The business is a commodity spread business: earnings track the gap between PAN prices and the cost of its ortho-xylene (OX) feedstock, and that gap is shaped by Chinese and Korean import competition and India's anti-dumping duties. Management is now moving downstream into plasticisers (a 75,000 TPA plant) and into compressed biogas, aiming to make earnings less cyclical.
What the company does
IGPL converts ortho-xylene, a refinery-derived aromatic, into phthalic anhydride by catalytic vapour-phase oxidation. Its original process technology came from Lurgi of Germany, which was a technical and financial collaborator when the project was promoted. The plant was conceived as a 100% Export-Oriented Unit (EOU) with a licensed capacity of 45,000 tpa. At the time, that made it the largest PAN plant in India and larger than the typical 35,000 tpa international plant.
Over three decades the site has been expanded in phases (PA-1 to PA-5) to 2,22,110 MTPA. The Company also earns revenue from:
Maleic anhydride (MAN): recovered from wash water generated in PAN production, so it is effectively a by-product monetisation stream. Capacity is 7,660 MTPA across four units.
Benzoic acid: a further by-product and derivative stream.
Diethyl phthalate (DEP): a PAN derivative used in personal care products, incense sticks, cosmetics and toiletries. A debottlenecking programme is under way.
Plasticisers (new): a 75,000 TPA greenfield plant at Taloja producing DOP, DINP and DIPP. It reached mechanical completion in March 2026, and management expects commercial production in September–October 2026.
Compressed biogas (new): a CBG plant run through IG Biofuels Limited, processing organic waste. Mechanical completion is targeted for Q2 FY2027 and operations for Q3 FY2027.
Business and revenue model
The revenue model is entirely product sales: bulk industrial chemicals sold by the tonne to manufacturers. There is no service, subscription or licensing revenue. Pricing is set by the market and moves with international PAN benchmarks (Asian CFR prices) and OX feedstock costs, so profitability depends on the PAN–OX spread rather than on list pricing.
Non-PAN revenue (MAN, benzoic acid, DEP and others) is still small. Management disclosed non-PAN revenue of ₹49 cr in Q1 FY2027, about 8% of quarterly revenue.
Value-chain position
IGPL is a mid-stream intermediate producer:
Upstream: refiners and aromatics producers supply ortho-xylene. Indian refiners are a source, and imports are available because Taloja is close to the JNPT and Mumbai ports.
IGPL: converts OX into PAN and recovers MAN, benzoic acid and DEP.
Downstream: customers include plasticiser makers (phthalates for flexible PVC), paint and coatings makers (alkyd resins), unsaturated polyester resin (UPR) and fibreglass composite makers, and dye and pigment producers (for example copper phthalocyanine).
End-markets: PVC cables, leather cloth, footwear, flooring, automotive, construction, paints and infrastructure.
The plasticiser project integrates IGPL one step forward. It will consume its own PAN and sell plasticisers directly to PVC compounders, capturing part of the margin that currently goes to its customers.
Customer types and end-markets
Customers are industrial B2B buyers. The main segments are plasticiser manufacturers, paint companies (alkyd resin makers), UPR and composites producers, pigment and dye producers, and makers of agro and food intermediates (for MAN). Domestic sales dominate. Exports were about 10% of revenue in Q1 FY2027, against roughly 20% cited in a broker initiation note several years earlier, so the export share has fallen as domestic demand absorbed added capacity.
The Company's own description vs. independent characterisation
Company framing (investor presentations): IGPL presents itself as India's largest PAN manufacturer and among the top five globally. Its stated vision is to become a well-diversified chemicals company while keeping its leadership position in phthalic anhydride. The FY2026 Directors' Report frames the plasticiser plant as positioning the Company for the growing Indian plasticiser market.
Independent characterisation: IGPL is a scale-advantaged, cyclical, single-site, single-molecule commodity producer. It sits low on the domestic cost curve: proximity to the port lowers logistics costs, the site is large, and by-product recovery adds revenue. Earnings are still dominated by a spread it does not control, as shown by EBITDA moving from ₹407 cr (FY2022) to ₹105 cr (FY2024), back to ₹221 cr (FY2025) and down to about ₹101 cr (FY2026). The current capex cycle (PA-5, plasticisers, DEP, CBG) is the first serious attempt to break that dependence. Its success will decide whether the stock earns a structurally higher multiple.
Strategy
Stated strategy
In its investor presentations and Annual Reports, IGPL describes three strategic themes:
-
Defend PAN leadership: keep about 50% domestic share, run at high utilisation and stay the low-cost producer through scale (five plants at one site), port proximity and by-product recovery.
-
Diversify into non-PAN chemistry: grow MAN, benzoic acid and DEP (debottlenecking) to raise the non-PAN revenue share. The vision statement is to become a well-diversified chemicals company while remaining the PAN leader.
-
Forward integration and green diversification: the 75,000 TPA plasticiser plant and the CBG project.
Initiative register (last 24 months)
| Initiative | Announced / status | Investment | Target / metric | Status (Oct 2026) |
|---|---|---|---|---|
| PA-5 PAN plant | Production from 12 Feb 2024 | — | Raises PAN capacity to 2,22,110 MTPA | Operating |
| Advance plasticiser plant (DOP, DINP, DIPP), Taloja | Board approval 2024; completion pushed to Mar 2026 (Nov 2025) | ₹165 cr excluding GST | 75,000 TPA; 2,000–2,500 t/month initially; FY2027 about 15,000–25,000 t; FY2028 about 50,000–65,000 t | Mechanically complete Mar 2026; commercial start guided Sep–Oct 2026 |
| DEP debottlenecking | FY2026–FY2027 | — | FY2027 DEP volume about 8,000–12,000 t | In progress |
| CBG plant (IG Biofuels Ltd) | Launched FY2025; up to ₹100 cr investment approved Nov 2025 | About ₹32 cr project | Mechanical completion Q2 FY2027; operations Q3 FY2027 | Under construction |
| Effluent treatment plant upgrade | 2024 presentation | — | Environmental compliance | Commissioned (per presentation) |
| Trade-remedy advocacy (anti-dumping duty) | ADD extended from 1 Aug 2026 | — | ADD about US$40/t on China and about US$140/t on Korea (per management) | In force for five years |
Guidance and medium-term targets
Management does not give EBITDA margin or profit guidance, citing market volatility and geopolitical uncertainty (Q1 FY2027 call coverage). Operational guidance for FY2027:
-
PAN volume about 2,00,000 t (after shutdowns at two plants);
-
Plasticisers about 20,000–25,000 t annualised for FY2027, ramping to 50,000–65,000 t (some coverage says up to 75,000 t) in FY2028;
-
DEP about 8,000–12,000 t;
-
Plasticiser EBITDA margin 10–12%; annual interest and depreciation for the plasticiser plant about ₹10 cr each.
Products & Services
Pricing model: spot and contract prices linked to market; no list pricing is disclosed. Management estimates the plasticiser business typically earns 10–12% EBITDA margins, with net margins averaging about 4–5% over the last four to five years (Q1 FY2027 concall).
Brands: IGPL sells under its corporate name; no consumer brands.
Product Portfolio
| Product | Description and chemistry | Key applications / target customers | Capacity and status | Notes |
|---|---|---|---|---|
Phthalic anhydride (PAN) | C8H4O3; made by catalytic oxidation of ortho-xylene; sold as flakes or molten | Phthalate plasticisers (DOP/DEHP, DINP, DIDP) for flexible PVC; alkyd resins (paints); unsaturated polyester resins; copper phthalocyanine pigments; dyes | 2,22,110 MTPA across five plants (PA-1 to PA-5); PA-5 started 12 Feb 2024; FY2027 volume guidance about 2,00,000 t, allowing for shutdowns at two plants | Core product; domestic share about 50%; protected by anti-dumping duty extended from 1 Aug 2026 |
Maleic anhydride (MAN) | C4H2O3; recovered from PAN wash water | UPR, alkyd resins, agro and food intermediates, lubricant additives | 7,660 MTPA across four units | IGPL says it is India's only MAN producer; Indian MAN demand was about 55,000 MTPA (older company presentation), so India relies heavily on imports |
Benzoic acid (BA) | Aromatic carboxylic acid; by-product / derivative stream | Preservatives, plasticisers, alkyd resins, intermediates | — | Part of non-PAN revenue |
Diethyl phthalate (DEP) | Ester of PAN and ethanol | Personal care, cosmetics, incense sticks, toiletries, fragrance fixative | Debottlenecking under way; FY2027 volume guidance about 8,000–12,000 t | Higher-value PAN derivative |
Plasticisers — DOP / DEHP | Dioctyl phthalate; general-purpose PVC plasticiser | PVC compounders: cables, flooring, leather cloth, footwear | Part of 75,000 TPA plant; mechanical completion Mar 2026 | Commercial start guided for Sep–Oct 2026 |
Plasticisers — DINP | Diisononyl phthalate; higher-molecular-weight, lower-volatility plasticiser | Automotive, wire and cable, flooring | Part of 75,000 TPA plant | Faces some regulatory scrutiny in export markets |
Plasticisers — DIPP | Phthalate-family plasticiser (exact grade as named by management) | PVC compounding | Part of 75,000 TPA plant | Product specification not detailed in sources reviewed |
Compressed biogas (CBG) | Methane-rich biogas from organic waste | Gas marketing companies (likely under India's SATAT scheme; offtake partner not confirmed), industrial users | About ₹32 cr project; mechanical completion targeted Q2 FY2027; operations Q3 FY2027 | Run through IG Biofuels Limited |
"Advance plasticisers" | Referred to in some database profiles as an 8,400 MTPA "Advance Plasticizers" capacity | Not specified | Status unclear | Discrepancy: the Company calls the new 75,000 TPA project the "Advance Plasticizer plant"; the 8,400 MTPA figure may be an older or smaller product line. |
Financial Narrative
Basis: consolidated Ind AS financials, ₹ crore, unless stated. Main sources: Screener.in consolidated history (FY2022–FY2025), Tapetide consolidated series (FY2025–FY2026), company Directors' Reports for FY2025 and FY2026 (standalone), Muthoot Securities standalone P&L, and NSE results filings.
Income statement
Notes and flags:
-
FY2025 and FY2026 depreciation are derived as EBITDA + other income − interest − PBT. FY2026 other income is the standalone figure (total revenue ₹1,953.67 cr less revenue from operations ₹1,924.98 cr). FY2026 interest (≈₹41 cr) comes from MarketScreener/Zonebourse data, not a filing.
-
FY2025 standalone figures from the Company: revenue from operations ₹2,206.23 cr; total revenue ₹2,233.97 cr; PBT ₹144.33 cr; PAT ₹112.47 cr. FY2026 standalone: revenue from operations ₹1,924.98 cr (−12.7%); total revenue ₹1,953.67 cr (−12.5%); PBT ₹31.36 cr; PAT ₹23.16 cr.
-
FY2026 consolidated PAT of about ₹2 cr is the sum of quarterly consolidated net profit (Q1 −13, Q2 −2, Q3 −11, Q4 +28) per Tapetide. Confirm against the audited FY2026 consolidated statements.
-
Dividends: FY2025 (₹10) and FY2026 (₹5) are confirmed from filings. FY2022–FY2024 DPS are derived from Screener's reported payout ratios (12%, 15%, 58%) multiplied by EPS; verify against the annual reports.
-
Diluted EPS equals basic EPS; there are no dilutive instruments in the sources reviewed.
Margin profile
The raw material ratios are calculated from Muthoot standalone data (FY2022: ₹1,233 cr on ₹1,883 cr; FY2023: ₹1,787 cr on ₹2,352 cr; FY2024: ₹1,749 cr on ₹2,099 cr; FY2025: ₹1,713 cr on ₹2,206 cr). Gross margin is not reported as such under Ind AS. Raw material intensity is the best proxy for the PAN–OX spread: the raw material share of revenue rose from 65.5% to 83.3% between FY2022 and FY2024 as the spread collapsed.
Revenue CAGR: FY2021–FY2026 (5 years) about 11.4% (₹1,124 cr to ₹1,925 cr). FY2022–FY2026 (4 years) about 0.6%. Five-year growth is almost entirely the FY2021–FY2022 price and volume upcycle plus PA-4 and PA-5 volumes; the last four years were flat.
Quarterly trajectory (consolidated, ₹ cr)
Source: Tapetide consolidated quarterly series, plus Sahi and ScanX reports of Company filings for Q1 FY2026 and Q1 FY2027 revenue. Q1 FY2027 consolidated revenue was ₹617.8 cr (+31.4% YoY) and consolidated PAT ₹66.44 cr (vs. a ₹12.99 cr loss). Standalone revenue was about ₹620 cr, standalone operating EBITDA ₹113 cr (vs. ₹2.2 cr; margin 18.25% vs. 0.47%), and standalone PAT ₹70.97 cr (vs. an ₹8.21 cr loss). Total income including other income was ₹625.1 cr.
Data-quality flag: one ScanX headline reported Q1 FY2027 consolidated EBITDA as "₹1,188 crore". That is inconsistent with revenue of ₹618 cr and is almost certainly a units error (about ₹118.8 cr). We have disregarded it.
Balance sheet (consolidated)
FY2025 net worth is derived from the reported book value of ₹431.06 per share × 3.0795 cr shares. The split of borrowings into short- and long-term, cash and equivalents, and net debt for FY2025–FY2026 were not available in the sources reviewed; see the audited balance sheets in the FY2025 and FY2026 Annual Reports. Goodwill appears negligible, since the business was built organically. Borrowings more than doubled from ₹173 cr (FY2022) to ₹368 cr (FY2024) to fund PA-5 and early plasticiser capex, and interest cost tripled from ₹13 cr to about ₹41 cr (FY2026). That indicates further borrowing growth after FY2024; FY2026 interest of about ₹41 cr implies gross debt in the region of ₹450–550 cr at 8–9% cost (analyst inference).
Cash flow (consolidated)
Investing cash flow is used as a capex proxy because it includes treasury investment movements; pure capex is not separated in the sources reviewed. FY2025 dividends paid (about ₹31 cr) is the cash payout of the FY2024-declared dividend, which could not be confirmed. The ₹30.8 cr figure is the FY2025 dividend (₹10/share) paid in FY2026. There have been no buybacks in the sources reviewed.
Interpretation: IGPL produced strong internal cash in upcycle years, but FY2022 OCF (₹109 cr) was well below EBITDA because working capital expanded (CCC 25 days, debtor days 67) during rising prices. FY2024 OCF of only ₹37 cr, combined with PA-5 capex, explains the jump in debt. Cumulative free cash flow over FY2022–FY2024 was negative.
Ratios
ROE and ROA are derived on average and closing balances respectively; FY2025 ROE matches Screener's 8.53%. ROCE comes from Screener (FY2021: 30%). CCC for FY2025–FY2026 comes from Tapetide. ROIC is not reported; ROCE serves as a proxy. The current ratio was not disclosed in the sources reviewed. Net debt/EBITDA cannot be computed reliably for FY2025–FY2026 without balance-sheet data; on FY2024 gross debt of ₹368 cr and EBITDA of ₹105 cr, gross debt/EBITDA was about 3.5x, a cyclical high.
Trend commentary
-
FY2022 peak: PA-4 volumes (commissioned December 2020) coincided with a global PAN spread spike, producing EBITDA of ₹407 cr at a 21.6% margin and ROCE of 35%.
-
FY2023 normalisation: revenue grew 25% on price, but margins halved as OX costs rose faster than PAN prices.
-
FY2024 trough: Chinese capacity additions and weak export pricing compressed spreads. EBITDA margin fell to 5%, and Q3 FY2024 showed a negative operating profit of −₹6 cr. PA-5 was commissioned into a weak market.
-
FY2025 partial recovery: EBITDA +82% to ₹248 cr (standalone including other income) and PAT +183%, helped by PA-5 volumes and better spreads.
-
FY2026 second trough: revenue −12.7%, standalone PAT −79%. The decline came from plant shutdowns (management cited two-plant shutdowns and "plant shutdown impacts" in Q1 FY2026), weak paints demand (a prolonged monsoon also hurt peer Thirumalai), and narrow spreads. Three of four quarters were loss-making on a consolidated basis.
-
Q1 FY2027 inflection: an 18.25% standalone EBITDA margin was the strongest since FY2022. Management attributes it mainly to improved realisations and normalised operations. Sustainability depends on the PAN–OX spread and the renewed anti-dumping duty.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue from operations, consolidated | 2,099 | 2,206 | 1,925 |
Group Entities
| Entity | Relationship | Activity |
|---|---|---|
I G Petrochemicals Limited | Parent, listed | PAN, MAN, benzoic acid, DEP; plasticisers (from FY2027) |
IGPL International Limited | Subsidiary | International / trading activities (scope not detailed in sources reviewed) |
IGPL Energy Limited | Subsidiary | Energy-related activities (scope not detailed) |
IG Biofuels Limited | Subsidiary | Compressed biogas project; board approved investment of up to ₹100 cr (Nov 2025) |
IGPL Charitable Foundation | Subsidiary | CSR delivery |
IGPL (FZE) | Historical wholly owned subsidiary (UAE) | — |
Mysore Petro Chemicals Ltd | Promoter group company | Trading of OX, PAN, MAN, benzoic acid; former PAN/MAN producer |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr, consolidated) | 1,883 | 2,352 | 2,099 | 2,206 | 1,925 |
Revenue growth YoY (%) | 67.5 | 24.9 | -10.8 | 5.1 | -12.7 |
Other income (INR Cr) | 6 | 22 | 30 | 28 | 29 |
EBITDA excluding other income (INR Cr, consolidated) | 407 | 318 | 105 | 221 | 101 |
Interest (INR Cr) | 13 | 24 | 30 | 39 | 41 |
Depreciation (INR Cr) | 44 | 47 | 52 | 66 | 79 |
Profit before tax (INR Cr, consolidated) | 356 | 268 | 53 | 144 | 10 |
Effective tax rate (%) | 26 | 25 | 26 | 23 | 79 |
Net profit (INR Cr, consolidated) | 264 | 200 | 40 | 109 | 2 |
Net profit (INR Cr, standalone) | 264 | 200 | 40 | 112 | 23 |
EPS basic (₹, consolidated) | 85.89 | 64.95 | 12.83 | 35.4 | 0.6 |
EPS basic (₹, standalone) | 85.9 | 64.95 | 12.83 | 36.5 | 7.52 |
Dividend per share (INR) | 10 | 10 | 7.5 | 10 | 5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin (%) | 21.6 | 13.5 | 5.0 | 10.0 | 5.2 |
PBT margin (%) | 18.9 | 11.4 | 2.5 | 6.5 | 0.5 |
Net margin (%, consolidated) | 14.0 | 8.5 | 1.9 | 4.9 | 0.1 |
Raw material cost / revenue (%, standalone) | 65.5 | 76.0 | 83.3 | 77.7 | — |
Financial Analysis
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Revenue from operations | — | — | — | — | 470 | — | — | — | 618 |
Operating profit (EBITDA ex other income) | 62 | 63 | 47 | 47 | -1 | 20 | 8 | 67 | 112 |
Profit before tax | 45 | 34 | 36 | 25 | -16 | -1 | -13 | 40 | 90 |
Net profit | 35 | 26 | 29 | 19 | -13 | -2 | -11 | 28 | 66 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital (INR Cr) | 31 | 31 | 31 | 31 | 31 |
Reserves (INR Cr) | 1,031 | 1,204 | 1,216 | — | — |
Net worth (INR Cr) | 1,062 | 1,235 | 1,247 | 1,327 | — |
Book value per share (INR) | 345 | 401 | 405 | 431 | — |
Total borrowings (INR Cr) | 173 | 254 | 368 | — | — |
Other liabilities (INR Cr) | 416 | 503 | 520 | — | — |
Total assets (INR Cr) | 1,651 | 1,992 | 2,135 | — | — |
Net fixed assets (INR Cr) | 736 | 717 | 1,030 | — | — |
Capital work-in-progress (INR Cr) | 118 | 349 | 158 | — | — |
Investments (INR Cr) | 81 | 182 | 144 | — | — |
Other assets incl. working capital and cash (INR Cr) | 716 | 745 | 803 | — | — |
Goodwill and intangibles (INR Cr) | 0 | 0 | 0 | — | — |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 183 | 109 | 233 | 37 | — |
Investing cash flow (INR Cr) | -72 | -106 | -255 | -115 | — |
Financing cash flow (INR Cr) | -80 | -19 | 21 | 48 | — |
Net cash flow (INR Cr) | 30 | -15 | -2 | -29 | — |
Free cash flow, OCF + investing proxy (INR Cr) | 111 | 3 | -22 | -78 | — |
Dividends paid (INR Cr) | — | — | — | — | 31 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 28.0 | 17.4 | 3.2 | 8.5 | 0.2 |
ROCE (%) | 35 | 22 | 5 | 11 | — |
ROA (%) | 16.0 | 10.0 | 1.9 | — | — |
Debt / equity (x) | 0.16 | 0.21 | 0.30 | — | — |
EBITDA / interest (x) | 31.3 | 13.3 | 3.5 | 5.7 | 2.5 |
Asset turnover (x) | 1.14 | 1.18 | 0.98 | — | — |
Debtor days | 67 | 50 | 59 | — | — |
Inventory days | 45 | 34 | 42 | — | — |
Payable days | 87 | 76 | 79 | — | — |
Cash conversion cycle (days) | 25 | 8 | 21 | 13 | 23 |
Dividend payout (%) | 12 | 15 | 58 | 28 | — |
Share Price History
| Date | Price (INR) | Source |
|---|---|---|
27 Mar 2025 | 429.75 | Trendlyne |
10 Apr 2026 | 424.00 | ICICI Direct |
13 Apr 2026 | 413.20 | Kotak Neo |
10 Jul 2026 | 432.15 | IIFL |
20 Aug 2026 | 471.05 | InCred Money |
30 Sep 2026 | 587.70 | MarketScreener / Zonebourse (+47.83% year to date; +0.58% on the day) |
Valuation Multiples
| Multiple | IGPL | Basis |
|---|---|---|
Market cap (INR Cr) | 1,810 | ₹587.70 × 3.0795 cr shares |
P/E, trailing (x) | 22.3 | TTM consolidated PAT about ₹81 cr (Q2 FY2026 to Q1 FY2027) |
P/B (x) | 1.4 | BVPS about ₹422–431 |
Market cap / TTM EBITDA (x) | 8.7 | TTM EBITDA ₹207 cr |
Dividend yield (%) | 0.9 | ₹5 FY2026 DPS / ₹587.70 |
Income Statement
| Metric (INR Cr) | FY2024 | FY2025 | FY2026 | FY2027E | FY2028E |
|---|---|---|---|---|---|
Revenue | 2,099 | 2,206 | 1,925 | 2,456 | 2,935 |
EBITDA | 105 | 219 | 95 | 285 | 252 |
Interest paid | 30 | 39 | 41 | 37 | 31 |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 10 | 10 | 7.5 | 10 | 5 |
Credit Ratings
| Agency | Instrument | Rating | Outlook | Date |
|---|---|---|---|---|
India Ratings & Research (Fitch group) | Long-term bank facilities / term loans | IND AA- | Stable | Affirmed and assigned 14 Oct 2025 |
India Ratings & Research | Short-term / non-fund-based | IND A1+ | — | Affirmed 14 Oct 2025 |
Moody's / S&P / Fitch (global) | — | Not rated | — | — |
Analyst Conclusions
Management guidance (FY2027)
PAN volume is guided at about 2,00,000 t; plasticisers at about 15,000–25,000 t in FY2027 rising to 50,000–65,000 t in FY2028, at 10–12% EBITDA margins; DEP at 8,000–12,000 t; and CBG operations starting in Q3 FY2027. There is no margin or profit guidance.
Consensus
FY2027E revenue is about ₹2,456 cr and EBITDA about ₹285 cr. For FY2028E, revenue is about ₹2,935 cr and EBITDA about ₹252 cr.
Bull case
-
Cyclical upturn plus protection: Q1 FY2027's 18.25% standalone EBITDA margin, on a capacity base 27% larger than the FY2022 peak (PA-5), plus five years of anti-dumping cover. Sustained mid-teens margins would imply annual EBITDA above ₹350 cr.
-
Structural mix shift: a 75,000 TPA plasticiser plant at 10–12% margins adds a less volatile earnings stream that uses IGPL's own PAN.
-
Survivor advantage: Thirumalai's FY2026 consolidated loss of ₹202 cr and negative EBITDA leave IGPL as the financially strongest Indian PAN producer, which supports pricing discipline and share gains.
Bear case
-
Spread mean-reversion: in each of the past four years, one strong period was followed by a collapse. Chinese supply and OX volatility can quickly erase Q1 FY2027's gains, and the US$40/t duty on China is small.
-
Execution and dilution risk: the plasticiser plant is already about two quarters late. Plasticiser margins (10–12%) are below PAN's peak margins, and consensus shows FY2028 EBITDA falling despite higher revenue.
-
Concentration and balance-sheet risk: single-site operations (FY2026 shutdowns), rising debt and interest (coverage 2.5x in FY2026), and negative free cash flow in capex years.
Catalysts and monitorables (next 12 months)
-
Q2 FY2027 results (expected November 2026): whether spreads held after Q1.
-
Formal announcement of plasticiser commercial production and monthly run rates (target 2,000–2,500 t/month).
-
CBG commissioning in Q3 FY2027.
-
PAN–OX spread and Chinese export pricing.
-
Re-issue of the India Ratings rating (around Oct 2026).
-
Net debt and capex disclosures in the H1 FY2027 balance sheet.
-
Any segment reporting change.
-
Promoter holding and dividend policy.
Analyst verdict
I G Petrochemicals is a high-quality operator in a low-quality, cyclical product. Its competitive position has strengthened over the past three years. It holds about half of India's PAN market, operates the country's largest and lowest-cost capacity, carries an AA- rating, and stayed profitable through a down-cycle that pushed its nearest domestic rival into heavy losses. The renewal of anti-dumping duties to 2031 and the addition of PA-5 capacity give it more leverage to any recovery than at any time in its history. Q1 FY2027 showed that leverage: a standalone EBITDA margin of 18.25% on revenue up 31%.
The investment question, however, is not whether IGPL is the best PAN producer; it plainly is. The question is whether management can make earnings less cyclical. The record is mixed. Diversification has been slow, the non-PAN share is still under a tenth of revenue, and the plasticiser plant is roughly two quarters behind schedule. The plasticiser business also moves IGPL further into ortho-phthalates, which face growing regulatory scrutiny, and at lower margins than PAN at mid-cycle. Debt and interest have also risen steadily through the capex phase.
At about ₹588 per share (around 22x trailing earnings, about 1.4x book and about 9x trailing EBITDA before debt), the market has partly priced in recovery: the stock is up about 48% this year. The risk-reward now depends on whether spreads persist and plasticisers ramp up on schedule. If both hold, FY2027–FY2028 earnings could approach FY2023 levels, and the current valuation would look undemanding against a cash-generative, dividend-paying market leader. If spreads revert, as they have in each recent cycle, the shares trade back toward book value.
On balance, IGPL is a well-managed cyclical with an improving but not yet proven diversification story. It is best owned by investors who can monitor spreads closely, and who treat confirmation of plasticiser commercial production and Q2–Q3 FY2027 margins as the decisive checkpoints.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background (as disclosed) |
|---|---|---|
M M Dhanuka | Chairman (Promoter, Non-Executive / Executive status to verify) | Long-time promoter; listed as MD of Mysore Petro Chemicals; background in chemicals sales, marketing and commercial roles |
Nikunj Dhanuka | Managing Director & CEO (Promoter) | Leads strategy and diversification; MD & CEO per 2021 investor presentation and current profiles |
Pramod Bhandari | Chief Financial Officer | Led the Q1 FY2027 earnings call (7 Aug 2026) |
Sudhir R Singh | Company Secretary & Compliance Officer | Signs exchange filings (2019–2025) |
Sanjoy Datta | Director (role to verify) | Appointed at Nov 2025 board meeting |
Executive Director | — | Responsible for Taloja plant per 2021 presentation |
Major Shareholders
| Holder category | % holding (Dec 2025) |
|---|---|
Promoter and promoter group (Indian) | 68.74 |
Foreign promoter | 0.00 |
Public (all non-promoters) | 31.26 |
Of which: institutions (FII, DII, MF), indicative | about 4.5 |
Competitive Landscape
Key Competitors
| Competitor | Country | Segment overlap | Relative positioning |
|---|---|---|---|
Thirumalai Chemicals Ltd (TCL) | India | PAN, MAN, fumaric and malic acid | #2 domestic PAN producer; diversified into food acids (including a US facility); FY2026 revenue ₹1,735 cr; consolidated loss of about ₹202 cr |
Asian Paints Ltd (captive PAN) | India | PAN (captive for alkyd resins) | Captive consumer and producer; reduces merchant demand |
Mysore Petro Chemicals Ltd | India | PAN / MAN trading | Promoter-group affiliate; trading only |
Aditya Chemicals (historical) | India | PAN | — |
BASF SE | Germany | PAN, plasticisers | Historically the world's largest PAN producer (about 400,000 tpa at ten sites per 2007 reports); global price-setter |
Nan Ya Plastics Corp. | Taiwan | PAN, plasticisers | Large integrated Asian producer and exporter |
Chinese PAN producers (several) | China | PAN | Main source of import pressure; covered by Indian anti-dumping duty |
Korean PAN producers (e.g., Aekyung Chemical) | South Korea | PAN, plasticisers | Exporters to India; subject to anti-dumping duty (about US$140/t per IGPL management) |
Polynt Group | Italy | PAN, MAN, resins | European integrated anhydrides and resins player |
Stepan Company | USA | PAN (polyols), surfactants | Western PAN producer, largely captive |
ExxonMobil Chemical | USA | DINP plasticisers | Global plasticiser leader; competitor for IGPL's new DINP output |
KLJ Group | India | Plasticisers (DOP, DINP, others) | Leading domestic plasticiser producer; main competitor in the new segment |
UPC Technology Corp. | Taiwan | PAN, plasticisers | Asian integrated PAN-to-plasticiser producer |
Peer Comparison FY2026
| Metric | IGPL | Thirumalai Chemicals |
|---|---|---|
FY2026 revenue (INR Cr, consolidated) | 1,925 | 1,735 |
FY2026 revenue growth (%) | -12.7 | -15.3 |
FY2026 EBITDA (INR Cr) | 101 | -23 |
FY2026 EBITDA margin (%) | 5.2 | -1.3 |
FY2026 net profit (INR Cr, consolidated) | 2 | -202 |
FY2025 EBITDA margin (%) | 10.0 | 2.3 |
Market cap (INR Cr) | about 1810 (30 Sep 2026) | about 2099 (mid-2026) |
PAN capacity (MTPA) | 222,110 | — |



